Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 14, 2026; 32(42): 122218
Published online Nov 14, 2026. doi: 10.3748/wjg.122218
Published online Nov 14, 2026. doi: 10.3748/wjg.122218
Figure 1 Flow chart of patient selection.
AFIF: Aurantii Fructus Immaturus Flavonoid; FAS: Full Analysis Set; SS: Safety Analysis Set; PPS: Per-Protocol Set.
Figure 2 Resolution rate of all four symptoms of functional dyspepsia after 4 weeks.
A: Full Analysis Set; B: Per-Protocol Set. FAS: Full Analysis Set; PPS: Per-Protocol Set.
Figure 3 Resolution rate of a single symptom of functional dyspepsia after 4 weeks.
A: Postprandial fullness; B: Early satiety; C: Upper abdominal burning sensation; D: Upper abdominal pain.
Figure 4 Resolution rate of all four symptoms of functional dyspepsia during treatment.
A: Full Analysis Set; B: Per-Protocol Set. FAS: Full Analysis Set; PPS: Per-Protocol Set.
Figure 5 Resolution rate of a single symptom of functional dyspepsia during treatment.
A: Postprandial fullness; B: Early satiety; C: Upper abdominal burning sensation; D: Upper abdominal pain.
Figure 6 Subgroup analysis of four traditional Chinese medicine syndrome types.
CI: Confidence interval.
- Citation: Wan Q, Wang YY, Li XY, Liu Y, Jia BY, Han M. Aurantii Fructus Immaturus Flavonoid tablets for functional dyspepsia: A multicenter, double-blind, dose-exploring IIb randomized controlled trial. World J Gastroenterol 2026; 32(42): 122218
- URL: https://www.wjgnet.com/1007-9327/full/v32/i42/122218.htm
- DOI: https://dx.doi.org/10.3748/wjg.122218